Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 7.700-8.100 for the period, compared to the consensus estimate of 7.600. The company issued revenue guidance of $28.2 billion-$28.6 billion, compared to the consensus revenue estimate of $28.4 billion.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on GILD shares. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday. Robert W. Baird upped their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Thursday. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Royal Bank of Canada increased their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $101.33.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $103.31 on Thursday. The stock has a market cap of $128.75 billion, a P/E ratio of 1,147.89, a P/E/G ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock’s fifty day moving average is $93.38 and its 200 day moving average is $87.24. Gilead Sciences has a one year low of $62.07 and a one year high of $104.71.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Sell-side analysts anticipate that Gilead Sciences will post 4.35 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Insider Activity

In related news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock worth $53,611,715 in the last three months. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.